TY - JOUR
T1 - CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma
AU - Tong, Luqing
AU - Li, Jiabo
AU - Choi, John
AU - Pant, Ayush
AU - Xia, Yuanxuan
AU - Jackson, Christopher
AU - Liu, Peidong
AU - Yi, Li
AU - Boussouf, Elias
AU - Lim, Michael
AU - Yang, Xuejun
N1 - Funding Information:
Funding This work was supported by grants from the National Natural Science Foundation of China (No. 81872063) and the State Scholarship Fund from China Scholarship Council (No. 201806940031). ML is funded by Arbor, Aegenus, Altor, BMS, Accuray, and DNAtrix. This research received no external funding from these companies.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Glioma is the most common tumor in the central nervous system that portends a poor prognosis. Key genes negatively related to survival may provide targets for therapy to improve the outcome of glioma. Here, we report a protein-coding gene CLEC5A, which is the top 1 gene by univariate Cox regression analysis of 524 primary GBM samples. Expression of CLEC5A is significantly correlated with decreased overall survival in patients with glioma via large-scale analysis. An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma. Notably, this tumor-associated biomarker is expressed preferentially on myeloid cells over glioma cells. And it shows a strong co-expression with M2 macrophage biomarker. Furthermore, CLEC5A-associated genes are enriched in immunosuppressive biological processes. The silico flow cytometry also showed CLEC5A expression related to less tumor purity and more tumor-promoting leukocytes infiltration. In conclusion, we proposed a new M2 biomarker expressed on myeloid cells that may decrease survival in patients with glioma through immunosuppressive mechanisms.
AB - Glioma is the most common tumor in the central nervous system that portends a poor prognosis. Key genes negatively related to survival may provide targets for therapy to improve the outcome of glioma. Here, we report a protein-coding gene CLEC5A, which is the top 1 gene by univariate Cox regression analysis of 524 primary GBM samples. Expression of CLEC5A is significantly correlated with decreased overall survival in patients with glioma via large-scale analysis. An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma. Notably, this tumor-associated biomarker is expressed preferentially on myeloid cells over glioma cells. And it shows a strong co-expression with M2 macrophage biomarker. Furthermore, CLEC5A-associated genes are enriched in immunosuppressive biological processes. The silico flow cytometry also showed CLEC5A expression related to less tumor purity and more tumor-promoting leukocytes infiltration. In conclusion, we proposed a new M2 biomarker expressed on myeloid cells that may decrease survival in patients with glioma through immunosuppressive mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=85077163890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077163890&partnerID=8YFLogxK
U2 - 10.1038/s41417-019-0140-8
DO - 10.1038/s41417-019-0140-8
M3 - Article
C2 - 31591460
AN - SCOPUS:85077163890
SN - 0929-1903
VL - 27
SP - 669
EP - 679
JO - Cancer Gene Therapy
JF - Cancer Gene Therapy
IS - 9
ER -